ProPhase Labs, Inc. Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs
ProPhase Labs, Inc. (PRPH) reported Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs of $30.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts · last filed 2026-08-19
- ProPhase Labs, Inc. adjustments to additional paid in capital, stock issued, issuance costs for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- ProPhase Labs, Inc. adjustments to additional paid in capital, stock issued, issuance costs for the quarter ending 2026-03-31 was $30.00K, a 60.00% decline year-over-year.
- ProPhase Labs, Inc. adjustments to additional paid in capital, stock issued, issuance costs for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- ProPhase Labs, Inc. adjustments to additional paid in capital, stock issued, issuance costs for the quarter ending 2025-09-30 was $0.00.
- ProPhase Labs, Inc. adjustments to additional paid in capital, stock issued, issuance costs for fiscal 2025 was $275.00K, a 52.34% decline from fiscal 2024.
- ProPhase Labs, Inc. adjustments to additional paid in capital, stock issued, issuance costs for fiscal 2024 was $577.00K.
| Period end | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 3 month | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 6 month | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 9 month | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-08-19 | $30.00K 10-Q · filed 2026-08-19 | $30.00K derived: sum of 3 quarters · filed 2026-08-19 | $30.00K derived: sum of 4 quarters · filed 2026-08-19 |
| 2026-03-31 | $30.00K 10-Q/A · filed 2026-07-09 | $30.00K derived: sum of 2 quarters · filed 2026-07-09 | $30.00K derived: sum of 3 quarters · filed 2026-07-09 | $230.00K derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01 | $0.00 derived: sum of 2 quarters · filed 2026-06-01 | $200.00K derived: sum of 3 quarters · filed 2026-08-19 | $275.00K 10-K · filed 2026-06-01 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-19 | $200.00K derived: sum of 2 quarters · filed 2026-08-19 | $275.00K 10-Q · filed 2025-11-19 | $758.00K derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-06-30 | $200.00K 10-Q · filed 2026-08-19 | $275.00K 10-Q · filed 2026-08-19 | $758.00K derived: sum of 3 quarters · filed 2026-08-19 | $758.00K derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-03-31 | $75.00K 10-Q/A · filed 2026-07-09 | $558.00K derived: sum of 2 quarters · filed 2026-07-09 | $558.00K derived: sum of 3 quarters · filed 2026-07-09 | $652.00K derived: sum of 4 quarters · filed 2026-07-09 |
| 2024-12-31 | $483.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01 | $483.00K derived: sum of 2 quarters · filed 2026-06-01 | $577.00K derived: sum of 3 quarters · filed 2026-06-01 | $577.00K 10-K · filed 2026-06-01 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-19 | $94.00K derived: sum of 2 quarters · filed 2025-11-19 | $94.00K 10-Q · filed 2025-11-19 | |
| 2024-06-30 | $94.00K 10-Q · filed 2025-08-13 | $94.00K 10-Q · filed 2025-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |